© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Jackie Collins
Articles
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinoma
February 25, 2022
Article
Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Study highlights impact of immunotherapy response on timing of cytoreductive nephrectomy
September 11, 2021
Article
“From [the results] of this study, we propose the timing and indication of cytoreductive nephrectomy,” said Hiroshi Kikuchi, MD, PhD.
Apalutamide shows strong activity and adherence in real-world nmCRPC analysis
September 10, 2021
Article
“Our real-world study showed that PSA response to apalutamide and continuous androgen deprivation therapy was robust and consistent with that in the SPARTAN study,” said Benjamin H. Lowentritt, MD.